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Available online xxxxPatients with schizophrenia have a higher risk of cardiovascular diseases and higher mortality from them than
does the general population; however, the underlying mechanism remains unclear. Impaired cerebral autoregu-
lation is associatedwith cerebrovascular diseases and their mortality. Increased or decreased cerebral blood ﬂow
in different brain regions has been reported in patients with schizophrenia, which implies impaired cerebral
autoregulation. This study investigated the cerebral autoregulation in 21 patients with schizophrenia and 23
age- and sex-matched healthy controls. None of the participants had a history of cardiovascular diseases, hyper-
tension, or diabetes. All participants underwent 10-min blood pressure and cerebral blood ﬂow recording
through ﬁnger plethysmography and Doppler ultrasonography, respectively. Cerebral autoregulation was
assessed by analyzing two autoregulation indices: the mean blood pressure and cerebral blood ﬂow correlation
coefﬁcient (Mx), and the phase shift between the waveforms of blood pressure and cerebral blood ﬂow deter-
mined using transfer function analysis. Compared with the controls, the patients had a signiﬁcantly higher Mx
(0.257 vs. 0.399, p = 0.036) and lower phase shift (44.3° vs. 38.7° in the 0.07–0.20 Hz frequency band, p =
0.019), which indicated impaired maintenance of constant cerebral blood ﬂow and a delayed cerebrovascular
autoregulatory response. Impaired cerebral autoregulation may be caused by schizophrenia and may not be an
artifact of coexisting medical conditions. The mechanism underlying impaired cerebral autoregulation in schizo-
phrenia and its probable role in the development of cerebrovascular diseases require further investigation.





Schizophrenia affects approximately 1% of the population. The af-
fected population has higher mortality and a 20% shorter life span
than does the general population (Brown, 1997). This gap has increased
in recent years (Saha et al., 2007). Cardiovascular diseases, including is-
chemic heart disease and cerebrovascular diseases, are themajor causes
of death other than suicide or injury in patients with schizophrenia
(Bushe et al., 2010; Curkendall et al., 2004; Olfson et al., 2015). Further-
more, both the incidence of cardiovascular diseases and the associatedaipeiMedical University Shuang
w Taipei City, Taiwan.
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5mortality are about 2 times higher in patients with schizophrenia than
in the general population (Curkendall et al., 2004; Lin et al., 2008).
Previous studies have reported that cardiovascular diseases in pa-
tients with schizophrenia reduced their life span by 15–20 years
(Nordentoft et al., 2013). Factors such as underlying psychiatric ill-
nesses, medications, metabolic syndrome, life habits, and the availabili-
ty and accessibility of medical services have been proposed to explain
the high incidence and mortality rate of cardiovascular diseases in pa-
tients with schizophrenia; however, the exact reason remains uncer-
tain. It has generally been believed that antipsychotic medications
account for the development of metabolic syndrome (Zimmermann et
al., 2003). However, mortality from cardiovascular diseases in schizo-
phrenic patients is not proportional to their cumulative exposure to
antipsychotics (Torniainen et al., 2015). Furthermore, use of second-on is impaired in schizophrenia: A pilot study, Schizophr. Res. (2017),
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syndrome but not in higher morbidity and mortality from cardiovascu-
lar diseases than does use of ﬁrst-generation antipsychotics (Bushe et
al., 2010). Therefore, factors other than medications andmetabolic syn-
drome may be responsible for the development of cardiovascular dis-
eases in patients with schizophrenia.
Studies using positron emission tomography (PET) or single photon
emission computed tomography have revealed that schizophrenia in-
creases or decreases the resting-state cerebral blood ﬂow (CBF) in
many brain regions (Andreasen et al., 1997; Kanahara et al., 2013;
Malaspina et al., 2004), and alterations in the resting-state CBF have
been associated with the clinical symptoms of schizophrenia through
PET or perfusion magnetic resonance imaging (Lahti et al., 2006; Zhu
et al., 2015). Furthermore, studies involving transcranial Doppler ultra-
sonography revealed that patients with schizophrenia had smaller CBF
changes while performing tasks than did healthy controls (Owega et
al., 1998; Sabri et al., 2003; Schuepbach et al., 2002). Therefore, it ap-
pears that the mechanism of maintaining an adequate CBF is impaired
in patients with schizophrenia.
Cerebral autoregulation (CA) is a physiologicalmechanism formain-
taining adequate CBF despite changes in blood pressure (BP) (van Beek
et al., 2008). The brain is a high-blood-demand organ because of its high
energy consumption, and impaired CA results in cerebral hypo- or hy-
perperfusion, which could affect the pathogenesis or outcome of neuro-
logical diseases. CA is assessed by analyzing the correlationbetween CBF
and BP. In the current study, we used Doppler ultrasonography and ﬁn-
ger plethysmography to record changes in CBF and peripheral BP, re-
spectively. The test was conducted when the participants were in the
resting state with spontaneous ﬂuctuations in CBF and BP. The advan-
tage of this method is its acceptable reliability and validity. Standard
testing protocols have been recommended on the basis of a consensus
among experts (Claassen et al., 2016). Presumably, during spontaneous
ﬂuctuations in CBF and BP, the changes in CBF are smaller and restored
faster than those in BP in participants with intact CA.
Impaired CA has been observed in cerebrovascular diseases, such as
ischemic stroke, hemorrhagic stroke, and carotid artery stenosis (Otite
et al., 2014; Petersen et al., 2015; Reinhard et al., 2005; Reinhard et al.,
2003; Reinhard et al., 2008). Furthermore, impaired CA has been ob-
served in traumatic brain injury (Czosnyka et al., 1996), migraine with
aura (Reinhard et al., 2008), and Alzheimer's disease (den Abeelen et
al., 2014). Vascular dysfunction and an increased risk of stroke have
been observed in migraine and Alzheimer's disease (Chi et al., 2013;
Hu et al., 2016). In a study on subarachnoid hemorrhage, patients with
worse CA had a higher risk of secondary vasospasm and cerebral ische-
mia than did patients with better CA (Otite et al., 2014). Therefore, im-
paired CA is associated with an increased risk of subsequent cerebral
ischemia.
The changes in CBF in patients with schizophrenia are different from
those in healthy people, implying the impairment of CA in patients with
schizophrenia. Furthermore, impaired CA is associated with the risk of
subsequent cerebrovascular diseases, which may explain the higher in-
cidence of cerebrovascular diseases in patients with schizophrenia than
in healthy people. However, a study providing evidence of impaired CA
in patients with schizophrenia is thus far unavailable. In this study, CA
was compared between patients with schizophrenia and healthy peo-
ple. Speciﬁcally, we hypothesized that in a resting state with spontane-
ous CBF and BP ﬂuctuations, the changes in CBF in patients with
schizophrenia would be larger and slower than those in healthy people.
2. Methods
2.1. Participants and clinical assessment
This study was approved by the Institutional Review Board of Taipei
Medical University, and all participants providedwritten informed con-
sent. Patients with a diagnosis of schizophrenia at the outpatient clinic,Please cite this article as: Ku, H.-L., et al., Cerebral blood ﬂow autoregulati
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ward at Taipei Medical University, Shuang Ho Hospital were enrolled
in this study. Each patient was in a stable psychiatric condition. None
of the patients had a history of cardiovascular diseases. Healthy volun-
teers without a history of cardiovascular diseases, mood disorders, or
sleep disorders were recruited from the community as controls. The
controls did not use any medicine when the study was conducted. By
contrast, the patients with schizophrenia used several types of medi-
cines including antipsychotics, antidepressants, mood stabilizers, and
hypnotics. The medicines of the patients are listed in Supplementary
Table 1. The participants were instructed not to consume caffeinated
drinks or heavy meals on the day of the CA test.
The diagnoses of the patients were conﬁrmed by trained psychia-
trists using a structured psychiatric diagnostic interview according to
the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edi-
tion, Text Revision (DSM- IV-TR). None of the patients reported a histo-
ry of substance dependence within 6 months prior to the study,
electroconvulsive therapy within 6 months prior to the study, or head
injurywith consciousness loss. The psychiatric condition of each patient
was evaluated by trained psychiatrists according to the Positive and
Negative Syndrome Scale (PANSS) (Kay et al., 1987).
2.2. Cerebral autoregulation assessment
In this study, the protocol of CA assessment, consisting of signal
acquisition, signal processing, and algorithm analysis, was performed
according to the white paper of the International Cerebral Autoregula-
tion Research Network (CARNet) (Claassen et al., 2016). In brief, each
participant was tested in the supine position with a head elevation of
30° and spontaneous breathing. Signals were recorded after a 15-min
rest, and a stable end-tidal carbon dioxide (CO2) level was conﬁrmed
through capnography (Nellcor N85, Medtronic, USA) because changes
in CO2 levels in blood can affect CBF; however, the data of end-tidal
CO2 levels were not used in the CA algorithm. Beat-to-beat BP was non-
invasively recorded through ﬁnger plethysmography (Finometer Pro,
Finapres, the Netherlands). CBFwas assessed by continuously recording
the blood ﬂow velocity (BFV) in the extracranial internal carotid artery
(ICA) by using a Doppler ultrasonographic monitoring system
(MultiDop-T, DWL, Germany) with two 2-MHz probes ﬁxed on the
upper neck and an insonation depth of 40–50 mm. The BP and BFV
were digitally recorded simultaneously for 10 min for each participant
at a sampling rate of 50 Hz by using a laptop computer equipped with
a data acquisition device (NI USB-6221 BNC, National Instruments,
USA) and signal processing software (DataDemon, DynaDx, USA).
Two methods were applied for evaluating CA: calculation of the
mean BP and mean BFV correlation coefﬁcient (Mx) and transfer func-
tion analysis (TFA). Mx was calculated as follows: Pearson's correlation
coefﬁcients between 20 consecutive 3-s periods (1min) ofmean BP and
mean BFV were calculated, and the 10 correlation coefﬁcients of 10min
were averaged (Czosnyka et al., 1996; Reinhard et al., 2003). The ratio-
nale behind using Mx as a CA index is that the change in BFV is consid-
ered independent of the change in BP in people with intact CA;
therefore, Mx=0 represents intact CA, whereasMx= 1 represents ab-
sent CA. TFA is a frequency domain analysis that calculates the “phase
shift” and “gain” between the cerebral BFV and BP waveforms at very
low frequency (VLF, 0.02–0.07 Hz), low frequency (LF, 0.07–0.20 Hz),
and high frequency (HF, 0.20–0.50Hz) (Claassen et al., 2016). The CA al-
gorithm used in this study was obtained from the website of CARNet
(http://www.car-net.org/content/resources). Under normal physiologi-
cal conditions, spontaneous oscillations are observed in cerebral BFV
and BP even when an individual is in a resting state. The changes in ce-
rebral BFV are generally restored faster than those in BP in people with
intact CA, resulting in a phase shift between the waveforms of cerebral
BFV and BP. Furthermore, the gain indicates that CA attenuates the
change in BFV compared with that in BP; therefore, a low gain repre-
sents efﬁcient CA (van Beek et al., 2008). In people with impaired CA,on is impaired in schizophrenia: A pilot study, Schizophr. Res. (2017),
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(Reinhard et al., 2005; Reinhard et al., 2008), and the phase shift at LF
between the cerebral BFV and BP is lower than that in healthy people
(Petersen et al., 2015; Reinhard et al., 2008).
2.3. Statistical analysis
Nonparametric statistical analysis was applied because of the
nonnormal distribution of the data. We compared continuous and cate-
gorical variables between the patients and healthy controls by using the
Mann–Whitney U test and Fisher's exact test, respectively. The correla-
tion between the variables was tested using Spearman's rank correla-
tion coefﬁcient. The data were expressed as the median and
interquartile range (IQR), and p b 0.05 was considered statistically sig-
niﬁcant. Statistical data were analyzed using PASW Statistics for Win-
dows version 18.0 (SPSS Inc., Chicago, IL, USA) and MedCalc Statistical
Software version 16.8 (MedCalc Software bvba, Ostend, Belgium;
https://www.medcalc.org; 2016).
3. Results
The characteristics of the participants are listed in Table 1. In this
study, 21 patients with schizophrenia (median age = 42 years, six
males) and 23 healthy controls (median age = 42 years, ﬁve males)
were analyzed. None of the participants had a history of cardiovascular
diseases, hypertension, or diabetes mellitus. The patients and controls
did not differ in age, sex, body mass index (BMI), and tobacco smoking
habits. Themedian duration of illness in the patientswith schizophrenia
was 9 years (IQR: 5–20 years) and themedian PANSS scorewas 67 (IQR:
63–79). At the time of the study, all patients received stable doses of an-
tipsychotics [median chlorpromazine (CPZ) equivalent = 563 mg/day,
IQR: 375–731 mg/day].
A comparison of CA indices between the patientswith schizophrenia
and controls is presented in Fig. 1 and Supplementary Table 2.Mx in the
patients was signiﬁcantly higher than that in the controls (0.399 vs.
0.257, p = 0.036, Fig. 1A). TFA revealed that the phase shift at LF in
the patients was signiﬁcantly lower than that in the controls (38.7° vs.
44.3°, p = 0.019, Fig. 1B), and the phase shift at VLF in the patients
was lower than that in the controls, but the difference was borderline
signiﬁcant (57.2° vs. 66.6°, p = 0.076, Fig. 1B). The phase shift at HF
(Fig. 1B) and gains at all frequency bands (Fig. 1C) did not differ signif-
icantly between the patients and controls. The Mx, phase shift at all fre-
quency bands, and gain at all frequency bands in the patients did not
signiﬁcantly correlate with the PANSS score or its subdomains, duration
of illness, CPZ equivalents of antipsychotics, and BMI (p N 0.05 for
Spearman's rank correlation coefﬁcient, data not shown).Table 1
Characteristics of the study participants.
Controls
N = 23
Median age (years)-median (IQR) 42 (32–53)
Sex: male (%) 5 (21.7%)
Body mass index-median (IQR) 23.5 (21.0–2
Hypertension (%) 0 (0%)
Diabetes mellitus (%) 0 (0%)
Tobacco smoking habit (%) 1 (4%)
Duration of illness (years)-median (IQR) (N.A.)
PANSS-median (IQR) (N.A.)
CPZ equivalents-median (IQR) (N.A.)
Mean arterial pressure (mmHg)-median (IQR) 82 (66–93)
Cerebral blood ﬂow velocity (cm/s)-median (IQR) 39 (36–43)
End-tidal carbon dioxide (mmHg)-median (IQR) 37 (35–40)
IQR = interquartile range, PANSS = Positive and Negative Syndrome Scale, CPZ = chlorproma
N.A. = not applicable.
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The poorer Mx and phase shift in the patients with schizophrenia
comparedwith the controls indicated the impairedmaintenance of con-
stant CBF and a delayed cerebrovascular autoregulatory response; how-
ever, none of the patients had a history of cerebrovascular disease,
hypertension, or diabetes. Therefore, the impaired CA of the patients
could not be explained by the presence of a preexisting cerebrovascular
disease. Furthermore, the CA indices of the patients did not correlate
with the CPZ equivalents, PANSS score, or duration of illness. To our
knowledge, this is the ﬁrst study to report impaired CA in patients
with schizophrenia.
The median value of Mx in our controls (0.257) was consistent with
those reported by Reinhard et al. (2005) and Reinhard et al. (2008)
(Mx = 0.20 and 0.28, respectively) in controls. The median value of
the phase shift in our controls (44.3° at LF) was consistent with those
in controls reported by Petersen et al. (2015) (47° at LF), Reinhard et
al. (2005) (48° at LF), and Reinhard et al. (2008) (40° at LF). Themedian
value of Mx in our patients with schizophrenia (0.399) was higher than
that in patients with stroke reported by Reinhard et al. (2005) (Mx =
0.27). The median value of phase shift in our patients with schizophre-
nia (38.7° at LF) was consistent with those of patients with stroke re-
ported by Petersen et al. (2015) (29.6° at LF) and Reinhard et al.
(2005) (39° at LF). Therefore, the alterations of CA indices in patients
with schizophrenia are comparable with those in patients with cerebro-
vascular diseases.
The mechanism of CA is complex and incompletely understood,
but CA has been proposed to control CBF by adjusting the vascular re-
sistance of cerebral small vessels through myogenic, neurogenic, and
metabolic mechanisms (Cipolla, 2009; van Beek et al., 2008). Vascu-
lar endothelial derived nitric oxide (NO) is responsible for vasodila-
tion, which reduces the vascular resistance and increases CBF
(Cipolla, 2009; Toda et al., 2009). Inhibition of NO synthase resulted
in CA impairment in a study on human participants (White et al.,
2000); therefore, the production of NO affects CA. NO and its related
biochemical pathways are associated with the pathogenesis of
schizophrenia through oxidative stress and disturbances in
neurodevelopment (Nasyrova et al., 2015). Compared with healthy
controls, the plasma NO levels were lower in patients with schizo-
phrenia before antipsychotic treatment (Lee and Kim, 2008;
Nakano et al., 2010) and higher in patients with schizophrenia re-
ceiving antipsychotic treatment (Maia-de-Oliveira et al., 2012). An
increased NO level was found in the postmortem brain tissues of pa-
tients with schizophrenia (Yao et al., 2004). Therefore, the produc-
tion and metabolism of NO are disturbed in patients with
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Fig. 1. Box andwhiskerwith dot plots of cerebral autoregulation indices of the controls and schizophrenic patients: (A)Mx, (B) phase shift, (C) gain. *pb 0.05between the two groups. VLF:
very low frequency, LF: low frequency, HF: high frequency.
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consequence of schizophrenia requires further investigation.
Considering that the use of antipsychotics would increase the level
of NO, the use of antipsychotics possibly alters CA. However, in the cur-
rent study, the CA indices, which were impaired in the patients with
schizophrenia, including Mx and the phase shift at VLF and LF, were
not correlated with the CPZ equivalents. Differences in the effects of an-
tipsychotics on CA may explain the absence of the correlation. There-
fore, CPZ equivalents cannot be used as surrogates for estimating the
correlation of antipsychotics with CA. Furthermore, CA involves a com-
plexmechanism. The effect of an increasedNO level on CA thus far is not
clear, and antipsychoticsmay affect CA through other biochemical path-
ways. To our knowledge, no study has addressed the effect of antipsy-
chotics on CA. In the current study, the possibility that the impaired
CA in patients with schizophrenia resulted from the use of antipsy-
chotics could not be excluded. Nevertheless, because CA correlated
with neither CPZ equivalents nor the duration of illness (therefore the
duration of antipsychotics use), the impaired CA cannot be explained
only by the use of antipsychotics.
Inadequate CBF has been reported in many brain regions of patients
with schizophrenia (Andreasen et al., 1997; Kanahara et al., 2013; Zhu
et al., 2015). Inadequate CBF could be interpreted as an inadequatemet-
abolic demand of speciﬁc neural networks or impaired CA of speciﬁc re-
gions; however, in the current study, distinguishing between these two
conditions was not possible. A study involving the induction of changes
in BP and recording of task-based functional brain images may answer
this question. In the current study, we assessed CA by measuring the
BFV of the ICA, which represented the CBF of the entire forebrain and
not of a speciﬁc region; however, a severe CA impairment of a speciﬁc
brain region could affect the CA indices calculated from the CBF of the
entire forebrain. Therefore, whether the impaired CA is a regional or
general disturbance in the forebrain could not be answered by this
study. Further investigation of the spatial distribution of CA impairment
in schizophrenia may provide not only answers to the aforementioned
questions but also clues regarding the pathomechanism.
Evidence supports the role of vascular disorder in schizophrenia.
Patients with schizophrenia had wide retinal venules before expo-
sure to antipsychotics, and these results were consistent in two co-
horts (Meier et al., 2015; Meier et al., 2013). Wide retinal venules
were also present in the healthy co-twins of patients with schizo-
phrenia (Meier et al., 2015), implying that the vascular disorder is
a genetic disorder manifesting before the onset of schizophrenic
symptoms and is not a consequence of schizophrenia or medical
treatment. Retinal vessels originate from the central nervous system
and reﬂect the condition of cerebral microvessels. Wide retinal ve-
nules are associated with inﬂammation, atherosclerosis, cerebral
small vessel disease, and the onset of cerebrovascular diseases
(Cheung et al., 2013; Ikram et al., 2006; McGeechan et al., 2009). A
functional genomics study involving genome-wide associationPlease cite this article as: Ku, H.-L., et al., Cerebral blood ﬂow autoregulati
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vasoregulation, shear stress-induced endothelial function, cerebral
ischemia, postischemic repair, and neurodevelopment was altered
in schizophrenia (Moises et al., 2015). This indicates that vascular
disorder, particularly microvascular dysfunction, is present in
schizophrenia (Gutterman et al., 2016; Moises et al., 2015); howev-
er, whether this vascular disorder contributes to the
pathomechanism of psychiatric symptoms remains unclear. Further-
more, whether the severity of psychiatric symptoms is associated
with the severity of vascular disorders remains unclear. In this
study, the PANSS score and its subdomains were not associated
with CA indices. However, the small intragroup variation of disease
severity in patients explains this ﬁnding. The IQR of the PANSS scores
of our patients was 63–79; therefore, most of our patients were ho-
mogeneously “moderately ill” (Leucht et al., 2005). Finding a signif-
icant correlation between parameters with small variations is
difﬁcult in a small sample. A more reliable method to ﬁnd the corre-
lation between CA and symptoms is to enroll patients with different
severities. Nevertheless, impaired CA and an increased risk of cere-
brovascular diseases could be expected in patients with schizophre-
nia according to emerging evidence of vascular dysfunction in them.
This study has some limitations. First, the sample size was relatively
small; however, the patients and controls did not differ in age, sex, and
vascular comorbidities. Therefore, we could compare CA between the
patients and controls with a small sample size and without known con-
founding factors. A larger sample size will be required to precisely ana-
lyze the correlation between CA and coexisting factors, such as
comorbidities or medications. Second, we could not exclude the effects
of antipsychotics on CA in this study. However, for conﬁrming the ef-
fects of antipsychotics on CA, recruiting drug-naive patients with
schizophrenia and observing the CA before and after using antipsy-
chotics are necessary. However, such a study would be difﬁcult in prac-
tice. Third, most of our patients had moderately severe symptoms. In a
relatively small sample with similar disease severity, the generalizabili-
ty of the study conclusions is limited and requires more investigation.
Fourth, we did not record the waist circumference, lipid levels, and
fasting glucose of the participants on the day of the CA test, andwhether
these factors differed between the patients and controls is not clear.
Nevertheless, the BMIs did not differ between the patients and controls,
and none of the participants had diabetes. The lipid proﬁles have not
been found to affect CA. Therefore, the lack of these datamay not appre-
ciably affect our conclusions.
In conclusion, we found the impaired maintenance of constant CBF
and a delayed cerebrovascular autoregulatory response in patients
with schizophrenia. The impaired CA may be caused by schizophrenia
and may not be an artifact of coexisting medical conditions. The mech-
anism of impaired CA in schizophrenia requires further investigation,
and it may play a role in not only the development of cerebrovascular
diseases but also the pathomechanism of schizophrenia.on is impaired in schizophrenia: A pilot study, Schizophr. Res. (2017),
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